中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
21期
205-206
,共2页
张银铃%田莹莹%袁希英%吕宏宇%马学真
張銀鈴%田瑩瑩%袁希英%呂宏宇%馬學真
장은령%전형형%원희영%려굉우%마학진
丝裂霉素%奈达铂%恶性胸腔积液%胸腔内灌注
絲裂黴素%奈達鉑%噁性胸腔積液%胸腔內灌註
사렬매소%내체박%악성흉강적액%흉강내관주
mitomycin%nedaplatin%malignant pleural effusion%intrapleural infusion
目的 观察丝裂霉素联合奈达铂治疗非小细胞肺癌( NSCLC )所致恶性胸腔积液的临床疗效及治疗相关的不良反应.方法 将69例患者随机分为丝裂霉素+奈达铂组( S组) 34例和甘露聚糖肽+奈达铂组(G组)35例,S组接受丝裂霉素4~6 mg+0. 9%氯化钠注射液50 mL及奈达铂50~80 mg+0. 9%氯化钠注射液50 mL,G组接受奈达铂50~80 mg+0. 9%氯化钠注射液50 mL及甘露聚糖肽40~60 mg+0. 9%氯化钠注射液30 mL,胸腔内灌注.结果 S组与G组胸腔积液的完全缓解(CR)率分别为52. 94%和22. 86%,有效率分别为94. 12%和51. 43%,差异有统计学意义( P<0. 05),且S组胸腔内化疗药物灌注次数明显少于G组( P<0. 05).两组主要不良反应是白细胞及血小板减少、恶心、呕吐及胸痛,其中S组及G组的Ⅰ+Ⅱ度血小板减少发生率分别为38. 23%和14. 29%( P<0. 05 ) ,Ⅲ度血小板减少发生率分别为26. 47%和0 ( P<0. 05 ) ,S组及G组胸痛发生率分别为32. 35%和11. 43%( P<0. 05 ) ,但均为轻度胸痛.结论 丝裂霉素联合奈达铂胸腔内灌注治疗NSCLC所致恶性胸腔积液效果较好,治疗相关不良反应易于接受.
目的 觀察絲裂黴素聯閤奈達鉑治療非小細胞肺癌( NSCLC )所緻噁性胸腔積液的臨床療效及治療相關的不良反應.方法 將69例患者隨機分為絲裂黴素+奈達鉑組( S組) 34例和甘露聚糖肽+奈達鉑組(G組)35例,S組接受絲裂黴素4~6 mg+0. 9%氯化鈉註射液50 mL及奈達鉑50~80 mg+0. 9%氯化鈉註射液50 mL,G組接受奈達鉑50~80 mg+0. 9%氯化鈉註射液50 mL及甘露聚糖肽40~60 mg+0. 9%氯化鈉註射液30 mL,胸腔內灌註.結果 S組與G組胸腔積液的完全緩解(CR)率分彆為52. 94%和22. 86%,有效率分彆為94. 12%和51. 43%,差異有統計學意義( P<0. 05),且S組胸腔內化療藥物灌註次數明顯少于G組( P<0. 05).兩組主要不良反應是白細胞及血小闆減少、噁心、嘔吐及胸痛,其中S組及G組的Ⅰ+Ⅱ度血小闆減少髮生率分彆為38. 23%和14. 29%( P<0. 05 ) ,Ⅲ度血小闆減少髮生率分彆為26. 47%和0 ( P<0. 05 ) ,S組及G組胸痛髮生率分彆為32. 35%和11. 43%( P<0. 05 ) ,但均為輕度胸痛.結論 絲裂黴素聯閤奈達鉑胸腔內灌註治療NSCLC所緻噁性胸腔積液效果較好,治療相關不良反應易于接受.
목적 관찰사렬매소연합내체박치료비소세포폐암( NSCLC )소치악성흉강적액적림상료효급치료상관적불량반응.방법 장69례환자수궤분위사렬매소+내체박조( S조) 34례화감로취당태+내체박조(G조)35례,S조접수사렬매소4~6 mg+0. 9%록화납주사액50 mL급내체박50~80 mg+0. 9%록화납주사액50 mL,G조접수내체박50~80 mg+0. 9%록화납주사액50 mL급감로취당태40~60 mg+0. 9%록화납주사액30 mL,흉강내관주.결과 S조여G조흉강적액적완전완해(CR)솔분별위52. 94%화22. 86%,유효솔분별위94. 12%화51. 43%,차이유통계학의의( P<0. 05),차S조흉강내화료약물관주차수명현소우G조( P<0. 05).량조주요불량반응시백세포급혈소판감소、악심、구토급흉통,기중S조급G조적Ⅰ+Ⅱ도혈소판감소발생솔분별위38. 23%화14. 29%( P<0. 05 ) ,Ⅲ도혈소판감소발생솔분별위26. 47%화0 ( P<0. 05 ) ,S조급G조흉통발생솔분별위32. 35%화11. 43%( P<0. 05 ) ,단균위경도흉통.결론 사렬매소연합내체박흉강내관주치료NSCLC소치악성흉강적액효과교호,치료상관불량반응역우접수.
Objective To observe the clinical curative efficacy and adverse reactions of mitomycin combined with nedaplatin injected into thoracic cavity in the treatment of malignant pleural effusion from non-small cell lung cancer ( NSCLC ) . Methods 69 NSCLC patients with malignant pleural effusion were randomly divided into mitomycin+nedaplatin group ( group S, 34 cases ) and mannatide+nedaplatin group ( group G, 35 cases ) . The mitomycin group was treated with 4-6 mg mitomycin+50 mL 0. 9% sodium chloride injection and 50-80 mg nedaplatin+50 mL 0. 9% sodium chloride injection injected into thoracic cavity, the mannatide group was treated with 50-80 mg nedaplatin+50 mL 0. 9% sodium chloride injection and 40-60 mg+30 mL 0. 9% sodium chloride injection. Results The CR and effective rate were 52. 94%, 22. 86% and 94. 12%, 51. 43% in group S and group G respectively ( P < 0. 05 ) . The times of pleural infusion chemotherapy was less in group S than that in group G ( P < 0. 05 ) . The major adverse reactions in two groups were leukocytopenia, thrombocytopenia, nausea, vomitus and chest pain. Incidence rates of Grade Ⅰ+Ⅱ and Ⅲ thrombocytopenia were 38. 23%, 14. 29% and 26. 47%, 0 in group S and group G respectively ( P < 0. 05 ) . Incidence rates of chest pain in group S and group G were 32. 35% , 11. 43% respectively ( P < 0. 05 ) , but all were mild chest pains. Conclusion Mitomycin combined with nedaplatin injected into thoracic cavity in the treatment of malignant pleural effusion from NSCLC is more efficient, the adverse reaction of the treatment could be accepted.
